HROW Stock - Harrow Health, Inc.
Unlock GoAI Insights for HROW
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $199.61M | $130.19M | $88.59M | $72.48M | $48.87M |
| Gross Profit | $150.37M | $90.55M | $63.21M | $54.26M | $34.41M |
| Gross Margin | 75.3% | 69.6% | 71.3% | 74.9% | 70.4% |
| Operating Income | $8.82M | $431,000 | $1.92M | $1.61M | $385,000 |
| Net Income | $-17,481,000 | $-24,411,000 | $-14,086,000 | $-18,007,000 | $-3,357,000 |
| Net Margin | -8.8% | -18.7% | -15.9% | -24.8% | -6.9% |
| EPS | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
HROWEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $0.40 | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.22 | $0.33 | +50.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $0.31 | $0.24 | -23.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.02 | $-0.38 | -2000.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $0.11 | $0.25 | +127.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.05 | $-0.12 | -140.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.25 | $-0.13 | +48.0% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.25 | $-0.28 | -12.0% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-0.05 | $-0.27 | -455.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.02 | $-0.09 | -467.8% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.01 | $-0.02 | -250.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.15 | $0.07 | +146.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.00 | $-0.06 | -9577.4% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.00 | $0.01 | +3325.8% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.01 | $0.03 | +185.7% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $0.08 | $-0.01 | -112.5% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.00 | $0.05 | +1139.5% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Latest News
Frequently Asked Questions about HROW
What is HROW's current stock price?
What is the analyst price target for HROW?
What sector is Harrow Health, Inc. in?
What is HROW's market cap?
Does HROW pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HROW for comparison